Drug
Molnupiravir
Molnupiravir: highest development phase Phase 3, developed by Merck, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Molnupiravir NCT06667700 | Phase 3 | Coronavirus Disease (COVID-19) |
| Molnupiravir 200 mg NCT04405570 | Phase 2 | SARS-CoV-2 Infection, COVID-19 |
Latest
No recent events.
Follow Molnupiravir on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.